GHRP-2

Hexapeptide growth hormone releasing peptide with the strongest GH release amplitude among the GHRP class. Activates GHS-R1a with moderate appetite stimulation (less than GHRP-6). Raises cortisol and prolactin more than ipamorelin but less than GHRP-6. Dose-dependent GH release with clear plateau.

Half-life

15-60 minutes

Bioavailability

Systemic via subcutaneous injection

Route

subcutaneous

Evidence tier

T2 — Single-RCT or mechanistic

Optimization pillars

recovery · muscle

References

2 peer-reviewed

Dose ranges

Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.

conservative

100 mcg/injection 1-2x/day

GH support

moderate

100–200 mcg/injection 2-3x/day

Moderate GH elevation

aggressive

200–300 mcg/injection 3x/day

Maximum GH output

Monitoring

igf-1
fasting-glucose
cortisol
prolactin

Contraindications

active-cancer
diabetes-uncontrolled
pituitary-tumor

References

PMID:9150108GHRP-2 (KP 102), a potent and specific growth hormone-releasing peptide — Endocr J, 1997
PMID:10372583Comparison of growth hormone secretagogues — Growth Horm IGF Res, 1999

Notes

GHRP-2 produces the highest GH amplitude of any peptide in its class. The dose-response curve plateaus at roughly 200mcg — going higher does not produce proportionally more GH. It increases cortisol and prolactin, but the ratio of GH output to side effect burden is better than GHRP-6. It is the middle ground. Not as clean as ipamorelin. Not as messy as GHRP-6. Strongest raw output.

This is not medical advice

Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.

See GHRP-2 in a protocol matched to you